argenx SE (ARGX.BR)
EUR 610.0
(1.77%)
EUR 610.0
(1.77%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.13 Billion EUR | 176.16% |
| 2022 | 410.74 Million USD | -17.4% |
| 2021 | 497.27 Million USD | 1009.97% |
| 2020 | 44.8 Million EUR | -42.69% |
| 2019 | 78.16 Million EUR | 218.1% |
| 2018 | 24.57 Million EUR | -43.75% |
| 2017 | 43.68 Million EUR | 182.33% |
| 2016 | 15.47 Million EUR | 106.49% |
| 2015 | 7.49 Million EUR | 64.07% |
| 2014 | 4.56 Million EUR | 23.56% |
| 2013 | 3.69 Million EUR | 69.3% |
| 2012 | 2.18 Million EUR | 49.75% |
| 2011 | 1.45 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 477.63 Million EUR | 118.77% |
| 2024 Q1 | 401 Million USD | -1.58% |
| 2023 Q3 | 329.78 Million USD | 21.9% |
| 2023 Q1 | 219.14 Million USD | 25.83% |
| 2023 Q2 | 270.55 Million USD | 23.46% |
| 2023 FY | 1.13 Billion EUR | 176.16% |
| 2023 Q4 | 406.83 Million USD | 23.36% |
| 2022 FY | 410.74 Million USD | -17.4% |
| 2022 Q3 | 137.98 Million USD | 83.5% |
| 2022 Q4 | 174.16 Million USD | 26.22% |
| 2022 Q1 | 23.41 Million USD | -10.03% |
| 2022 Q2 | 75.19 Million USD | 221.18% |
| 2021 Q1 | 158.15 Million EUR | 1026.7% |
| 2021 FY | 497.27 Million USD | 1009.97% |
| 2021 Q2 | 312.24 Million USD | 97.43% |
| 2021 Q3 | 857 Thousand USD | -99.73% |
| 2021 Q4 | 26.02 Million USD | 2936.41% |
| 2020 Q4 | 14.03 Million EUR | 0.0% |
| 2020 FY | 44.8 Million EUR | -42.69% |
| 2020 Q2 | 22.38 Million EUR | 0.0% |
| 2019 Q1 | 40.93 Million EUR | 2779.29% |
| 2019 FY | 78.16 Million EUR | 218.1% |
| 2019 Q4 | 17.51 Million EUR | 100.63% |
| 2019 Q3 | 8.73 Million EUR | 2.02% |
| 2019 Q2 | 8.55 Million EUR | -79.09% |
| 2018 Q2 | 13.84 Million EUR | 101.54% |
| 2018 Q3 | 2.44 Million EUR | -82.34% |
| 2018 FY | 24.57 Million EUR | -43.75% |
| 2018 Q1 | 6.86 Million EUR | -33.43% |
| 2018 Q4 | 1.42 Million EUR | -41.83% |
| 2017 Q1 | 7.11 Million EUR | 93.52% |
| 2017 Q2 | 18.56 Million EUR | 160.87% |
| 2017 Q4 | 10.31 Million EUR | 34.09% |
| 2017 Q3 | 7.69 Million EUR | -58.56% |
| 2017 FY | 43.68 Million EUR | 182.33% |
| 2016 Q3 | 5.5 Million EUR | 45.64% |
| 2016 Q1 | 2.51 Million EUR | 32.96% |
| 2016 FY | 15.47 Million EUR | 106.49% |
| 2016 Q2 | 3.77 Million EUR | 50.51% |
| 2016 Q4 | 3.67 Million EUR | -33.21% |
| 2015 Q2 | 1.72 Million EUR | 31.8% |
| 2015 FY | 7.49 Million EUR | 64.07% |
| 2015 Q4 | 1.88 Million EUR | -26.43% |
| 2015 Q3 | 2.56 Million EUR | 48.66% |
| 2015 Q1 | 1.31 Million EUR | -26.42% |
| 2014 Q2 | 308.66 Thousand EUR | -34.19% |
| 2014 Q3 | 2 Million EUR | 550.83% |
| 2014 Q4 | 1.78 Million EUR | -11.35% |
| 2014 FY | 4.56 Million EUR | 23.56% |
| 2014 Q1 | 468.98 Thousand EUR | -49.81% |
| 2013 Q2 | 530.61 Thousand EUR | -5.18% |
| 2013 Q3 | 1.67 Million EUR | 215.1% |
| 2013 Q4 | 934.37 Thousand EUR | -44.12% |
| 2013 Q1 | 559.62 Thousand EUR | 0.0% |
| 2013 FY | 3.69 Million EUR | 69.3% |
| 2012 FY | 2.18 Million EUR | 49.75% |
| 2011 FY | 1.45 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | -24346.252% |
| ABIVAX Société Anonyme | 4.62 Million EUR | -24446.766% |
| Adocia SA | 2.15 Million EUR | -52658.422% |
| Aelis Farma SA | 9.05 Million EUR | -12428.231% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | -35898.289% |
| genOway Société anonyme | 20.04 Million EUR | -5558.408% |
| IntegraGen SA | 12.53 Million EUR | -8947.355% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -377959.179% |
| Neovacs S.A. | 533.41 Thousand EUR | -212551.024% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -67357.387% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -5729876.147% |
| Sensorion SA | 4.74 Million EUR | -23815.049% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -382683.468% |
| TME Pharma N.V. | 17 Thousand EUR | -6672288.694% |
| Valbiotis SA | 4.73 Million EUR | -23865.901% |
| TheraVet SA | 1.07 Million EUR | -105117.83% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -62917.004% |
| BioSenic S.A. | 543 Thousand EUR | -208796.147% |
| Celyad Oncology SA | 102 Thousand EUR | -1111964.782% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | -373.172% |
| Genfit S.A. | 28.56 Million EUR | -3870.965% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -54251.034% |
| Innate Pharma S.A. | 51.9 Million EUR | -2085.519% |
| Inventiva S.A. | 17.47 Million EUR | -6390.279% |
| MaaT Pharma SA | 2.22 Million EUR | -50811.404% |
| MedinCell S.A. | 9.16 Million EUR | -12283.254% |
| Nanobiotix S.A. | 30.05 Million EUR | -3673.724% |
| Onward Medical N.V. | 532 Thousand EUR | -213115.428% |
| Oryzon Genomics S.A. | 14.19 Million EUR | -7892.792% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -50834.265% |
| Oxurion NV | 263 Thousand EUR | -431195.087% |
| Pharming Group N.V. | 245.31 Million EUR | -362.386% |
| Poxel S.A. | 1.98 Million EUR | -57159.267% |
| GenSight Biologics S.A. | 1.26 Million EUR | -89426.92% |
| Transgene SA | 1.18 Million EUR | -95702.878% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 78.402% |
| Valneva SE | 153.71 Million EUR | -637.942% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 31434.422% |